You are here

Eli Lilly

J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances

J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances

Fierce Pharma

Boehringer Ingelheim

Flag link:

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

Endpoints

Flag link:

Lilly fends off Cialis generics with new patent settlement

Lilly fends off Cialis generics with new patent settlement

Fierce Pharma

erectile dysfunction

Flag link:

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Yahoo/Zacks.com

Gilead Sciences

Flag link:

Lilly revs up to challenge Pfizer, Novartis in breast cancer with abemaciclib 'priority' nod

Lilly revs up to challenge Pfizer, Novartis in breast cancer with abemaciclib 'priority' nod

Fierce Pharma

Flag link:

Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses

Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses

Bloomberg

Flag link:

Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court

Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court

Bloomberg

Teva Pharmaceutical

Flag link:

Eli Lilly pledges up to $52m to Purdue for improving injection tech

Eli Lilly pledges up to $52m to Purdue for improving injection tech

Drug Delivery Business News

Purdue Univeristy

Flag link:

Lilly’s Olumiant, spurned by FDA, gets nod from NICE

Lilly’s Olumiant, spurned by FDA, gets nod from NICE

Fierce Pharma

rheumatoid arthritis

Flag link:

BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits

BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits

Fierce Pharma

Boehringer Ingelheim

DTC advertising

Flag link:

Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field

Little Alder bags positive PhIII migraine data, but giant rivals are racing ahead in a crowded field

Endpoints

Alder Biopharma

clinical trials

Flag link:

Eli Lilly completes expansion of San Diego biotech center

Eli Lilly completes expansion of San Diego biotech center

Fierce Biotech

Flag link:

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Medical Marketing and Media

Flag link:

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Xconomy

Alzheimer's disease

Flag link:

Eli Lilly CEO David Ricks weighs in on drug costs and health reform

Eli Lilly CEO David Ricks weighs in on drug costs and health reform

CNBC

healthcare reform

Flag link:

5 Things You Didn't Know About Eli Lilly and Co

5 Things You Didn't Know About Eli Lilly and Co

Motley Fool

Flag link:

Lilly wins FDA nod for Humalog pre-filled Junior KwikPen device

Lilly wins FDA nod for Humalog pre-filled Junior KwikPen device

Drug Delivery Business News

Flag link:

J&J's Invokana lowers CV risk, but by enough to compete?

J&J's Invokana lowers CV risk, but by enough to compete?

BioPharma Dive

Boehringer Ingelheim

Flag link:

ADA: Merck, Pfizer notch success, but late with SGLT-2 data

ADA: Merck, Pfizer notch success, but late with SGLT-2 data

BioPharma Dive

SGLT2 inhibitor

Boehringer Ingelheim

Flag link:

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

Endpoints

Flag link: